Investigational drug · Phase 3
Radotinib
Also called: Supect, IY5511
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Chronic Myeloid Leukemia, Chronic Phase, CML, Chronic Phase, CML, Refractory.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
9
Any phase or sponsor naming "Radotinib"
First trial start
2018
Jun 25, 2018
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Radotinib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chronic Myeloid Leukemia, Chronic Phase
- CML, Chronic Phase
- CML, Refractory
- CML - Philadelphia Chromosome
- Parkinson Disease
Approved drugs for the same conditions: Chronic myeloid leukemia · Parkinson's disease · Hematology and blood cancers · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "Radotinib" as an intervention, largest first.
- Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase PatientsPivotal-lookingCompleted
Il-Yang Pharm. Co., Ltd.Industry
NCT01511289 · 242 participants · Start Aug 2011 · Primary completion Feb 2015
Drug: Imatinib; Radotinib · For: Leukemia; Leukemia, Myeloid; Leukemia, Myelogenous, Chronic, BCR-ABL Positive and 3 more
Sites: Jakarta, Indonesia; Batangas, Philippines; Manila, Philippines · 22 sites in all
- Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China)Pivotal-lookingActive, not recruiting
Il-Yang Pharm. Co., Ltd.Industry
NCT03722420 · 238 participants (planned) · Start Dec 28, 2018 · Primary completion Mar 3, 2023
Drug: Radotinib; Imatinib · For: Chronic Myeloid Leukemia, Chronic Phase
Sites: Beijing, China
- A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIsPivotal-lookingRecruiting
Il-Yang Pharm. Co., Ltd.Industry
NCT03459534 · 173 participants (planned) · Start Jun 25, 2018 · Primary completion Jun 30, 2027
Drug: Radotinib HCl · For: Chronic Myeloid Leukemia, Chronic Phase; CML, Chronic Phase; CML, Refractory and 1 more
Sites: Barnaul, Russia; Kirov, Russia; Moscow, Russia · 18 sites in all
- Efficacy and Safety of Dose Redution of Radotinib as a First Line Treament in Ph+ CMLActive, not recruiting
Il-Yang Pharm. Co., Ltd.Industry
NCT06665412 · 169 participants · Start Oct 24, 2024 · Primary completion Jul 15, 2027
Drug: Radotinib Hydrochloride · For: Chronic Phase Ph+ Chronic Myeloid Leukemia
Sites: Anyang-si, South Korea; Daegu, South Korea
- Philadelphia Chromosome Positive CML Patients Without Optimal Response or Tolerance to Bcr-Abl TKICompleted
Il-Yang Pharm. Co., Ltd.Industry
NCT01602952 · 85 participants · Start Jul 2008 · Primary completion Oct 2012
Drug: Radotinib · For: Leukemia; Leukemia, Myeloid; Leukemia, Myelogenous, Chronic, BCR-ABL Positive and 2 more
Sites: Mumbai, India; Daegu, South Korea; Jeonju, South Korea · 12 sites in all
- Radotinib as 3rd or Later Line Therapy in CP-CMLStatus unknown
Ulsan University HospitalAcademic, hospital or other
NCT02422719 · 73 participants (planned) · Start Apr 2015 · Primary completion Mar 2019
Drug: Radotinib · For: Chronic Myeloid Leukemia
Sites: Ulsan, South Korea
- Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's DiseaseActive, not recruiting
Il-Yang Pharm. Co., Ltd.Industry
NCT04691661 · 43 participants · Start Sep 9, 2021 · Primary completion Sep 2, 2026
Drug: Radotinib HCl 50 mg; Placebo · For: Parkinson Disease
Sites: Lille, France; Limoges, France; Lyon, France · 7 sites in all
Il-Yang Pharm. Co., Ltd.Industry
NCT06461078 · 24 participants · Start Jul 22, 2024 · Primary completion Sep 25, 2024
Drug: Radotinib HCl · For: Drug Kinetics
Sites: Seoul, South Korea
Asan Medical CenterAcademic, hospital or other
NCT02421926 · 0 participants · Start Oct 2014 · Primary completion May 2023
Drug: IDEAL-E observation (investigators choice of imatinib, nilotinib, dasatinib, radotinib) · For: Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Sites: Seongnam, South Korea; Ansan, South Korea; Busan, South Korea · 12 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Physiologically Based Pharmacokinetic Modeling for Mechanistic Analysis of Food Effects: A Case Study with Radotinib.
Kang M, Kim NY, Shin JS, et al. · Pharm Res 2026
- Modulating IL-1β-induced pro-atherogenic endothelial responses through drug repurposing.
Solanki K, Raja SR, Samanta S, et al. · Inflammopharmacology 2026
- Drug repurposing for glucosyltransferase inhibition for targeted oral biofilm disruption.
de Lucena FS, Logan MG, Lewis SH, et al. · NPJ Biofilms Microbiomes 2026
- Clinical pharmacokinetic characteristics and the food effect of radotinib.
Lee Y, Kim J, Kang M, et al. · Invest New Drugs 2026
- Computational Repurposing of Nilotinib and Radotinib as SIRT2 Inhibitors for Neurodegenerative Diseases.
Majrashi TA, Alshahrani MY, Asiri MA, et al. · J Mol Neurosci 2026
- Virtual screening and molecular dynamics simulations for drug repurposing against autophagy to attenuate blast in cereal plants.
Rahman S, Rahman A, Huang YM, et al. · Sci Rep 2026
Also in development for Chronic Myeloid Leukemia, Chronic Phase
- HS-10382MK-4208, Tern-701Phase 32 trials
Jiangsu Hansoh Pharmaceutical Co., Ltd. · Chronic Myeloid Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Chronic Myeloid Leukemia, Chronic Phase
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.